Twist Bioscience Management
Management criteria checks 4/4
Twist Bioscience's CEO is Emily Leproust, appointed in Apr 2013, has a tenure of 12.25 years. total yearly compensation is $7.62M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.52% of the company’s shares, worth $11.71M. The average tenure of the management team and the board of directors is 2.2 years and 8.7 years respectively.
Key information
Emily Leproust
Chief executive officer
US$7.6m
Total compensation
| CEO salary percentage | 8.99% |
| CEO tenure | 12.3yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2.2yrs |
| Board average tenure | 8.7yrs |
Recent management updates
Recent updates
Investors Don't See Light At End Of Twist Bioscience Corporation's (NASDAQ:TWST) Tunnel And Push Stock Down 25%
Jun 01
Twist Bioscience Q2 Earnings Preview: Innovative Products, Not Enough Buyers
May 01We're Interested To See How Twist Bioscience (NASDAQ:TWST) Uses Its Cash Hoard To Grow
Apr 25
Cutting-edge DNA Synthesis Platform And Cost Reductions Will Power Future Market Expansion
Twist Bioscience's innovative DNA synthesis platform and strategic process improvements aim to drive revenue growth and enhance net margins.Why Investors Shouldn't Be Surprised By Twist Bioscience Corporation's (NASDAQ:TWST) 26% Share Price Plunge
Mar 02Twist Bioscience: Valuation Is Weighing On The Stock
Feb 06Twist Bioscience (NASDAQ:TWST) Is In A Strong Position To Grow Its Business
Dec 26Twist Bioscience Corporation's (NASDAQ:TWST) Shareholders Might Be Looking For Exit
Nov 30Twist Bioscience: Path To Profitability Beginning To Take Shape
Nov 29Twist Bioscience: A Post-Earnings Assessment
Nov 18Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'
Nov 08Twist Bioscience (NASDAQ:TWST) Is In A Strong Position To Grow Its Business
Sep 25Investors Aren't Buying Twist Bioscience Corporation's (NASDAQ:TWST) Revenues
Aug 20Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)
Aug 04Twist Bioscience: Growing Customer Base And Technology Platform Make Me Like This Stock
Jul 26We Think Twist Bioscience (NASDAQ:TWST) Can Easily Afford To Drive Business Growth
Jun 10Twist Bioscience Corporation (NASDAQ:TWST) Shares Fly 29% But Investors Aren't Buying For Growth
May 04Twist Bioscience: NGS Is Taking Off
May 03Twist Bioscience Corporation (NASDAQ:TWST) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Feb 27Twist Bioscience: Strong Performance In A Soft Market
Feb 07Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet
Jan 31We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate
Jan 22Twist Bioscience Corporation's (NASDAQ:TWST) Price Is Right But Growth Is Lacking After Shares Rocket 44%
Dec 18Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans
Oct 05We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth
Jul 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$191m |
| Dec 31 2024 | n/a | n/a | -US$197m |
| Sep 30 2024 | US$8m | US$685k | -US$209m |
| Jun 30 2024 | n/a | n/a | -US$220m |
| Mar 31 2024 | n/a | n/a | -US$192m |
| Dec 31 2023 | n/a | n/a | -US$206m |
| Sep 30 2023 | US$8m | US$685k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$209m |
| Mar 31 2023 | n/a | n/a | -US$213m |
| Dec 31 2022 | n/a | n/a | -US$214m |
| Sep 30 2022 | US$6m | US$665k | -US$218m |
| Jun 30 2022 | n/a | n/a | -US$208m |
| Mar 31 2022 | n/a | n/a | -US$188m |
| Dec 31 2021 | n/a | n/a | -US$165m |
| Sep 30 2021 | US$1m | US$590k | -US$152m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$123m |
| Dec 31 2020 | n/a | n/a | -US$117m |
| Sep 30 2020 | US$7m | US$519k | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$147m |
| Mar 31 2020 | n/a | n/a | -US$147m |
| Dec 31 2019 | n/a | n/a | -US$141m |
| Sep 30 2019 | US$8m | US$477k | -US$108m |
| Jun 30 2019 | n/a | n/a | -US$96m |
| Mar 31 2019 | n/a | n/a | -US$86m |
| Dec 31 2018 | n/a | n/a | -US$77m |
| Sep 30 2018 | US$525k | US$362k | -US$71m |
Compensation vs Market: Emily's total compensation ($USD7.62M) is about average for companies of similar size in the US market ($USD6.04M).
Compensation vs Earnings: Emily's compensation has been consistent with company performance over the past year.
CEO
Emily Leproust (52 yo)
Dr. Emily Marine Leproust, Ph D., is Director of Atlas Data Storage, Inc. since May 2025. Dr. Leproust serves as Independent Director at CM Life Sciences, Inc. since September 2, 2020.She serves as an Ind...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$7.62m | 0.52% $ 11.7m | |
| President & COO | 2.8yrs | US$3.85m | 0.11% $ 2.6m | |
| Chief Financial Officer | 1.5yrs | US$5.01m | 0.032% $ 717.9k | |
| Senior VP | 3.8yrs | US$1.80m | 0.072% $ 1.6m | |
| Senior Vice President of Human Resources | 9.3yrs | US$2.01m | 0.073% $ 1.7m | |
| VP & Chief Accounting Officer | 2.2yrs | no data | 0.024% $ 534.4k | |
| Chief Technology Officer | 4.4yrs | no data | no data | |
| Chief Information Officer | less than a year | no data | no data | |
| Senior Vice President of Sales & Support | less than a year | no data | no data | |
| Chief Corporate Responsibility Officer & Senior VP of Corporate Affairs | less than a year | no data | no data | |
| Senior Vice President of Operations | 1.8yrs | no data | no data |
Experienced Management: TWST's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$7.62m | 0.52% $ 11.7m | |
| Independent Director | 11.8yrs | US$272.48k | 0.16% $ 3.7m | |
| Lead Independent Director | 11yrs | US$307.48k | 0.10% $ 2.3m | |
| Independent Director | 6.2yrs | US$284.98k | 0.040% $ 892.4k | |
| Independent Director | 8.7yrs | US$277.48k | 0.032% $ 731.7k | |
| Independent Director | 6.8yrs | US$284.98k | 0.029% $ 656.7k | |
| Independent Director | 3.9yrs | US$277.48k | 0.029% $ 646.4k |
Experienced Board: TWST's board of directors are considered experienced (8.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/03 13:06 |
| End of Day Share Price | 2025/07/02 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Twist Bioscience Corporation is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Gaurav Goparaju | Berenberg |